ESC Congress 2023 Marco Valgimigli gives his view on the results of the STOPDAPT-3 study and discusses the added value of the insights from this study in the optimization of antithrombotic therapy post-PCI.
Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.
ESC Congress 2023 In the QUEST study, the effect of qiliqiangxin was investigated in patients with HFrEF. Dr. Joseph Wu, president of the American Heart Association, shares his thoughts on the study and discusses which further studies are necessary.
What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.
ESC Congress 2023 The randomized NITRATE-CIN study found that dietary intake of inorganic nitrate reduced the risk of contrast-induced nephropathy by 70%, and improved renal and cardiovascular outcomes.
ESC Congress 2023 DICTATE-AHF investigated whether early initiation of dapagliflozin within 24h of AHF hospitalization would improve diuretic efficacy. Zachary Cox shares the results of this study.
"What is hypertriglyceridemia? We have to think particles", says Erik Stroes. In this video, he explains the relationship between triglyceride-risk lipoproteins and atherogenic risk.
The AZALEA-TIMI 71 trial, in which the efficacy of the factor XI/XIa inhibitor abelacimab was compared with rivaroxaban in patients with AF at moderate-to-high risk of stroke, has been stopped early due to an overwhelming reduction in bleeding.
Perry Elliott gives a brief overview on the history, diagnosis, imaging, and genetics of hypertrophic cardiomyopathy (HCM).
In an observational cohort study, higher plasma levels of eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), were associated with a lower 10-year risk of MACE. Adjustment for DHA level increased the protective effect of higher EPA levels.
In the biomarker study of SMASH 1, the authors demonstrated that NT-proBNP concentrations at baseline predict the risk of incident ventricular arrhythmias in adults with an ICD, independently of established risk factors.
A prespecified substudy of the PACMAN-AMI trial showed 1 year of alirocumab, on top of rosuvastatin, resulted in regression of the angiographic diameter stenosis of non-obstructive coronary lesions in acute MI patients, compared with an increase with placebo.